Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00871117
First received: March 26, 2009
Last updated: February 17, 2011
Last verified: February 2011
Results First Received: January 13, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Conditions: Diphtheria
Pertussis and/or Poliomyelitis Diseases
Tetanus
Interventions: Biological: GSK Biologicals'Kinrix®
Biological: Merck and Company's MMRII
Biological: Merck and Company's Varivax

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
478 subjects were enrolled, but 2 subjects who received a subject number were not vaccinated. Therefore the total amount of subjects used for the analysis is 476.

Reporting Groups
  Description
Kinrix + M-M-R II + Varivax Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
Kinrix + M-M-R II -> Varivax Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.

Participant Flow:   Overall Study
    Kinrix + M-M-R II + Varivax     Kinrix + M-M-R II -> Varivax  
STARTED     239     237  
COMPLETED     234     227  
NOT COMPLETED     5     10  
Lost to Follow-up                 5                 10  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Kinrix + M-M-R II + Varivax Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
Kinrix + M-M-R II -> Varivax Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
Total Total of all reporting groups

Baseline Measures
    Kinrix + M-M-R II + Varivax     Kinrix + M-M-R II -> Varivax     Total  
Number of Participants  
[units: participants]
  239     237     476  
Age  
[units: Years]
Mean ± Standard Deviation
  4.2  ± 0.41     4.2  ± 0.37     4.2  ± 0.39  
Gender  
[units: subjects]
     
Female     129     123     252  
Male     110     114     224  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Subjects With Booster Responses to Diphteria and Tetanus   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

2.  Primary:   Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (FHA) and Anti-pertactin (Anti-PRN) Booster Responses, Measured in Enzyme-Linked Immunosorbent Assay Units Per Milliliter (EL.U/mL)   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

3.  Primary:   Geometric Mean Titers (GMTs) for Antibodies to Poliovirus Types 1, 2 and 3   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

4.  Secondary:   Number of Subjects With Anti-D and Anti-T Antibody Concentrations Above Cut-off Value   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

5.  Secondary:   Geometric Mean Concentrations (GMCs) for Anti-D and Anti-T Antibodies   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

6.  Secondary:   GMCs for Anti-PT, Anti-FHA, Anti-PRN Antibodies   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

7.  Secondary:   Number of Subjects With an Anti-polio 1, 2, 3 Booster Response   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

8.  Secondary:   Number of Subjects Seroprotected Against Diphteria and Tetanus   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

9.  Secondary:   Number of Subjects Protected Against Poliovirus 1, 2 and 3   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

10.  Secondary:   Number of Subjects Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies   [ Time Frame: One month after Kinrix vaccination (Month 1), prior to Varivax vaccination for Kinrix + M-M-R II -> Varivax Group. ]

11.  Secondary:   Number of Subjects With Solicited Local and General Symptoms   [ Time Frame: Within 4 days (Day 0 to 3) after booster immunization * for Kinrix + M-M-R II -> Varivax Group before vaccination with Varivax ]

12.  Secondary:   Number of Subjects With Unsolicited Adverse Events   [ Time Frame: Up to 31 days (Day 0 through Day 30) after booster vaccination * for Kinrix + M-M-R II -> Varivax Group before vaccination with Varivax ]

13.  Secondary:   Number of Subjects With Serious Adverse Events (SAEs)   [ Time Frame: During the entire study period (from Day 0 to 6 months post-vaccination) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


No publications provided


Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00871117     History of Changes
Other Study ID Numbers: 111852
Study First Received: March 26, 2009
Results First Received: January 13, 2011
Last Updated: February 17, 2011
Health Authority: United States: Food and Drug Administration